Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (131-140 of 565) with videos related to

Pageof 57
Sort By:
Drugs|November 17, 2011
Role of genotyping in non-small cell lung cancer treatment: current statusLaura Bonanno, Adolfo Favaretto, Massimo Rugge, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2002
Beta-tubulin mutational analysis: tantalizing findingsRafael Rosell, Miquel Tarón, Carme Sarries, et al.
Expert Review of Anticancer Therapy|August 7, 2018
Therapeutic approaches for T790M mutation positive non-small-cell lung cancerIlaria Attili, Niki Karachaliou, PierFranco Conte, et al.
Current Opinion in Pharmacology|June 13, 2006
Predicting the outcome of chemotherapy for lung cancerRafael Rosell, Fabiana Cecere, Mariacarmela Santarpia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathwayRafael Rosell, Miquel Taron, Noemi Reguart, et al.
The Lancet. Respiratory Medicine|December 4, 2014
ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapyRafael Rosell, Niki Karachaliou, Juergen Wolf, et al.
Translational Lung Cancer Research|December 4, 2018
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLCNiki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 22, 2016
HER3 as a Therapeutic Target in CancerNiki Karachaliou, Chiara Lazzari, Alberto Verlicchi, et al.
Oncotargets and Therapy|July 30, 2019
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectivesNiki Karachaliou, Manuel Fernandez Bruno, Jillian Wilhelmina Paulina Bracht, et al.
Molecular Cancer|January 24, 2024
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical researchMaría González-Cao, Carlos Pedraz, Miguel Ángel Molina-Vila, et al.
Pageof 57

Showing results (131-140 of 565) with videos related to

Sort By:
Pageof 57
Drugs|November 17, 2011
Role of genotyping in non-small cell lung cancer treatment: current statusLaura Bonanno, Adolfo Favaretto, Massimo Rugge, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2002
Beta-tubulin mutational analysis: tantalizing findingsRafael Rosell, Miquel Tarón, Carme Sarries, et al.
Expert Review of Anticancer Therapy|August 7, 2018
Therapeutic approaches for T790M mutation positive non-small-cell lung cancerIlaria Attili, Niki Karachaliou, PierFranco Conte, et al.
Current Opinion in Pharmacology|June 13, 2006
Predicting the outcome of chemotherapy for lung cancerRafael Rosell, Fabiana Cecere, Mariacarmela Santarpia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathwayRafael Rosell, Miquel Taron, Noemi Reguart, et al.
The Lancet. Respiratory Medicine|December 4, 2014
ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapyRafael Rosell, Niki Karachaliou, Juergen Wolf, et al.
Translational Lung Cancer Research|December 4, 2018
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLCNiki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 22, 2016
HER3 as a Therapeutic Target in CancerNiki Karachaliou, Chiara Lazzari, Alberto Verlicchi, et al.
Oncotargets and Therapy|July 30, 2019
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectivesNiki Karachaliou, Manuel Fernandez Bruno, Jillian Wilhelmina Paulina Bracht, et al.
Molecular Cancer|January 24, 2024
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical researchMaría González-Cao, Carlos Pedraz, Miguel Ángel Molina-Vila, et al.
Pageof 57